Use of fluvastatin following percutaneous coronary intervention

Area of Science:

• Cardiology
• Pharmacoeconomics
• Preventive Medicine

Background:

• Percutaneous coronary intervention (PCI) use has risen, increasing the need for adjunctive therapies.
• Lipid-lowering medications, particularly statins, are frequently used alongside PCI.
• Previous studies, like the Lescol Intervention and Prevention Study, indicate statins reduce post-PCI cardiac events.

Purpose of the Study:

• To evaluate the cost-effectiveness of initiating statin therapy for all patients undergoing PCI.
• To assess the health benefits, including survival improvements, associated with statin use post-PCI.
• To consider the economic implications of fluvastatin as a low-cost statin option.

Main Methods:

• Economic analysis of statin initiation in PCI patients.
• Review of data from studies like the Lescol Intervention and Prevention Study.
• Assessment of cost per quality-adjusted life year (QALY) in the UK.

Main Results:

• Statin therapy post-PCI demonstrates a favorable cost-effectiveness, with significant health benefits.
• The cost is estimated at approximately pound 3207 per QALY in the UK.
• Fluvastatin is identified as the most affordable statin option.

Conclusions:

• Initiating statin therapy for all PCI patients is a cost-effective strategy.
• Statin use, especially low-cost options like fluvastatin, improves survival and reduces cardiac events post-PCI.
• Further economic evaluation is needed regarding current statin use patterns and potential switching to fluvastatin.